← Retour à la une
États-Unis · Agences & temps réel · PR Newswire

TheWell Bioscience Launches RocketCell™ AOF B27-Like, N2-Like, and N2B27-Like Supplements, Advancing NAMs and Future GMP Development

Publié par PR Newswire · États-Unis il y a 14 min
RocketCell™ Animal Origin-Free (AOF) Supplements
RocketCell™ Animal Origin-Free (AOF) Supplements · PR Newswire

Résumé détaillé

SOUTH BRUNSWICK TOWNSHIP, N.J., Nov. 12, 2026 /PRNewswire/ -- TheWell Bioscience, a developer of an integrated animal origin-free 3D cell culture platform, announced the launch of…

SOUTH BRUNSWICK TOWNSHIP, N.J., Nov. 12, 2026 /PRNewswire/ -- TheWell Bioscience, a developer of an integrated animal origin-free 3D cell culture platform, announced the launch of RocketCell™ S1, S2, and S3 Supplements, AOF, a new portfolio of animal origin-free supplements designed to support reproducible and scalable stem cell, neural, organoid, and other advanced cell culture applications.

The portfolio includes RocketCell™ S1 Supplement (B27-like), RocketCell™ S2 Supplement (N2-like), and RocketCell™ S3 Supplement (N2B27-like premix). The launch expands the company's end-to-end animal origin-free (AOF) portfolio, giving researchers additional tools to build human-relevant cell culture platforms for New Approach Methodologies (NAMs) and other advanced research applications.

Explore RocketCell™ Animal Origin-Free B27-Like, N2-Like, and N2B27-Like Supplements.

"Our goal is to help human-relevant platforms move beyond the research lab and ultimately toward GMP production and clinical translation," said John Huang, Ph.D., CEO of TheWell Bioscience. "RocketCell™ S1, S2, and S3 strengthen the animal origin-free tools available to researchers today. By synthetic hydrogels, integrating media, recombinant growth factors, cultureware, and workflow reagents, our end-to-end AOF platform supports the development of more standardized and reproducible human-relevant models for NAMs. This integrated approach also supports our long-term strategy to develop GMP-grade solutions for future biomanufacturing and clinical applications."

Reducing animal-origin components helps researchers better control culture inputs and minimize biological variability. RocketCell™ S1, S2, and S3 provide animal origin-free alternatives to conventional N2- and B27-type supplements for advanced cell culture workflows.

The supplements complement TheWell Bioscience's expanding AOF ecosystem, including RocketCell™ media, VitroGel® synthetic hydrogels, CytoGrow™ recombinant growth factors, VitroPrime™…

RocketCell™…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

À lire aussi